Traduction de «one of the short-term » (Néerlandais → Français) :

Therefore, organising consultation between both of these bodies for specific trials is also one of the short-term goals.
Therefore, organising consultation between both of these bodies for specific trials is also one of the short-term goals.

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities, and Standard & Poor’s had ratings of AA- for long-term and A-1+ for short-term maturities. Fitch had a long-term rating of AA and a short-term rating of F1+.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities and Standard & Poor’s had a rating of AA- and A-1+, for long-term and short-term maturities, respectively. Fitch had a long-term rating of AA and a short-term rating of F1+.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities and Standard & Poor’s had a rating of AA- and A-1+, for long-term and shortterm maturities, respectively.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

In order to accommodate the payment for the Alcon acquisition financial investments were kept short-term which resulted in lower yields.
En vue du paiement de l’acquisition d’Alcon, les placements financiers ont été effectués à court terme, ce qui a entraîné des rendements plus bas.

Trade receivables 10 391 8 310 2 081 7 817 Other current assets 2 575 2 102 473 2 149 Cash, short-term deposits and marketable securities 7 994 17 449 -9 455 14 166
Comptes clients 10 391 8 310 2 081 7 817 Autres actifs courants 2 575 2 102 473 2 149 Trésorerie, dépôts à court terme et titres de placement 7 994 17 449 -9 455 14 166 Total actifs courants 27 716 33 691 -5 975 30 440 Total actif 124 628 95 505 29 123 90 686

These focus points will be further analysed and evaluated so that avenues for improvement or clarification can be proposed in the short term.
These focus points will be further analysed and evaluated so that avenues for improvement or clarification can be proposed in the short term.

Interest expense increased by 26% to USD 496 million from USD 395 million in the prior year period as a result of the issuance of US dollar bonds in February 2009 and March 2010, a Euro bond in June 2009 and the increase of short-term debts through the commercial paper program.
Les charges d’intérêts ont augmenté de 26% à USD 496 millions, en comparaison d'USD 395 millions dans la même période de 2009, à la suite de l’émission d’emprunts obligataires en dollars émis en février 2009 et mars 2010 et d’un emprunt obligataire en euros émis en juin 2009 ainsi que de l’augmentation des dettes à court terme par le biais du programme de billets de trésorerie.

In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.
In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.